JP2022543112A5 - - Google Patents

Info

Publication number
JP2022543112A5
JP2022543112A5 JP2022506729A JP2022506729A JP2022543112A5 JP 2022543112 A5 JP2022543112 A5 JP 2022543112A5 JP 2022506729 A JP2022506729 A JP 2022506729A JP 2022506729 A JP2022506729 A JP 2022506729A JP 2022543112 A5 JP2022543112 A5 JP 2022543112A5
Authority
JP
Japan
Prior art keywords
cells
gene
sequence encoding
group
dux4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022506729A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543112A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/044635 external-priority patent/WO2021022223A1/en
Publication of JP2022543112A publication Critical patent/JP2022543112A/ja
Publication of JP2022543112A5 publication Critical patent/JP2022543112A5/ja
Pending legal-status Critical Current

Links

JP2022506729A 2019-08-01 2020-07-31 Ｄｕｘ４発現細胞およびそれらの使用 Pending JP2022543112A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962881840P 2019-08-01 2019-08-01
US62/881,840 2019-08-01
PCT/US2020/044635 WO2021022223A1 (en) 2019-08-01 2020-07-31 Dux4 expressing cells and uses thereof

Publications (2)

Publication Number Publication Date
JP2022543112A JP2022543112A (ja) 2022-10-07
JP2022543112A5 true JP2022543112A5 (enExample) 2023-08-08

Family

ID=72088403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506729A Pending JP2022543112A (ja) 2019-08-01 2020-07-31 Ｄｕｘ４発現細胞およびそれらの使用

Country Status (4)

Country Link
US (1) US20220267732A1 (enExample)
EP (1) EP4007596A1 (enExample)
JP (1) JP2022543112A (enExample)
WO (1) WO2021022223A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
US11473060B2 (en) 2020-12-30 2022-10-18 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into NK cells
CA3200509A1 (en) 2020-12-31 2022-07-07 Sonja SCHREPFER Methods and compositions for modulating car-t activity
WO2022251443A1 (en) * 2021-05-26 2022-12-01 FUJIFILM Cellular Dynamics, Inc. Methods to prevent rapid silencing of genes in pluripotent stem cells
WO2022269393A1 (en) * 2021-06-23 2022-12-29 Crispr Therapeutics Ag Engineered cells with improved protection from natural killer cell killing
EP4370544A2 (en) 2021-07-14 2024-05-22 Sana Biotechnology, Inc. Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
JP2024534771A (ja) * 2021-08-11 2024-09-26 サナ バイオテクノロジー，インコーポレイテッド 補体媒介性炎症反応を低減するための同種異系細胞療法のための遺伝子改変細胞
MX2024001443A (es) 2021-08-11 2024-05-15 Sana Biotechnology Inc Sistemas inducibles para alterar la expresión génica en células hipoinmunógenas.
WO2023086988A1 (en) * 2021-11-12 2023-05-19 Fred Hutchinson Cancer Center Dux4 polypeptides and nucleic acids for treating inflammatory and autoimmune conditions
MX2024007528A (es) 2021-12-23 2024-08-30 Sana Biotechnology Inc Linfocitos t del receptor de antígeno quimérico (car) para el tratamiento de enfermedades autoinmunitarias y métodos asociados.
US20250302953A1 (en) 2022-02-14 2025-10-02 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
US20240010991A1 (en) * 2022-07-01 2024-01-11 Janssen Biotech, Inc. Materials and methods for bioengineered ipsc populations
WO2024012420A1 (zh) * 2022-07-11 2024-01-18 士泽生物医药（苏州）有限公司 一种表达faslg的通用型细胞及其制备方法
JP2026501446A (ja) * 2022-12-16 2026-01-15 ゼルスマート バイオ‐ファーマシューティカル （スズホウ） シーオー．， エルティーディー． ユニバーサル細胞及びその製造方法
WO2025117331A1 (en) 2023-12-01 2025-06-05 Eli Lilly And Company Methods of making stem cell-derived islet-like cells, as well as populations and compositions including the same
WO2025230941A1 (en) 2024-04-30 2025-11-06 Satellite Biosciences, Inc. Hypoimmunogenic cell mixtures and methods of use thereof
WO2025230947A1 (en) 2024-04-30 2025-11-06 Satellite Biosciences, Inc. Engineered hepatocytes for secreting polypeptides
GB202415025D0 (en) * 2024-10-11 2024-11-27 Ospedale San Raffaele Srl Cell

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422251A (en) 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
HK1049515B (en) 1999-12-06 2006-01-13 Sangamo Biosciences Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
DE60143192D1 (de) 2000-02-08 2010-11-18 Sangamo Biosciences Inc Zellen zur entdeckung von medikamenten
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
WO2003016496A2 (en) 2001-08-20 2003-02-27 The Scripps Research Institute Zinc finger binding domains for cnn
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP1737498A2 (en) 2004-04-08 2007-01-03 Sangamo Biosciences Inc. Zinc finger proteins for treatment of neuropathic pain
JP4903689B2 (ja) 2004-04-08 2012-03-28 サンガモ バイオサイエンシズ インコーポレイテッド 神経障害および神経変性症状を治療するための方法と組成物
EP2650366B1 (en) 2005-10-18 2017-03-22 Precision Biosciences Rationally designed meganucleases with altered sequence specificity and DNA-binding affinity
EP3156062A1 (en) 2010-05-17 2017-04-19 Sangamo BioSciences, Inc. Novel dna-binding proteins and uses thereof
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
JP5996630B2 (ja) 2011-04-05 2016-09-21 セレクティスＣｅｌｌｅｃｔｉｓ コンパクトｔａｌｅ−ヌクレアーゼを作製する方法及びその使用
NZ629427A (en) 2012-02-29 2016-04-29 Sangamo Biosciences Inc Methods and compositions for treating huntington’s disease
CA2988854A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods
WO2018073787A2 (en) * 2016-10-19 2018-04-26 Fred Hutchinson Cancer Research Center Compositions and methods for reprogramming cells and for somatic cell nuclear transfer using duxc expression
KR20190103373A (ko) 2017-01-13 2019-09-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 면역조작된 만능 세포
CN110637083A (zh) 2017-03-20 2019-12-31 华盛顿大学 细胞及其使用和制备方法
WO2020028134A1 (en) * 2018-07-30 2020-02-06 Fred Hutchinson Cancer Research Center Methods and compositions for treating cancer

Similar Documents

Publication Publication Date Title
JP2022546317A5 (enExample)
Kuhlmann et al. Chimeric antigen receptor T-cell approaches to HIV cure
Gornalusse et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells
JP6516740B2 (ja) 幹細胞及びキメラ抗原受容体を介した抗腫瘍性ｔ細胞免疫の改変
Wu et al. Development of an inducible caspase-9 safety switch for pluripotent stem cell–based therapies
JP6346266B2 (ja) 操作されたジンクフィンガータンパク質ヌクレアーゼを使用するｔ細胞受容体遺伝子の標的化された破壊
US9228007B1 (en) Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
CN115298314A (zh) 基因表达调控的安全开关
US20190161530A1 (en) Chimeric antigen receptor t cell compositions
US20230272429A1 (en) Modification of blood type antigens
Goffinet et al. Efficient nonviral gene delivery into primary lymphocytes from rats and mice
JP2025061188A (ja) キメラサイトカイン受容体
JP2022512674A (ja) 人工トランス活性化因子による選択
KR20210116531A (ko) 영양 장애형 표피 수포증 치료약
Zhang et al. Adoptive T cell therapy following haploidentical hematopoietic stem cell transplantation
Su et al. Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies
KR20230043906A (ko) 영양 장애형 표피 수포증의 치료약
Amrolia et al. Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation
CN111499766B (zh) 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用
JP7807756B2 (ja) 所望の特異性を有するエフェクター細胞の製造方法
US11903969B2 (en) Genome editing of graft-derived T-cells for post-transplant immunotherapy
KR102906951B1 (ko) 내인성 항원 제시 기전을 이용한 저면역원성 줄기세포 및 이의 제조 방법
Moen Transfection of Stem Cells and Gene Therapy
EA053040B1 (ru) Универсальная клетка и способ ее получения
Wang et al. 187. Comprehensive Integration Site Analysis of One New Gene Therapy Vector AAV-rDNA